// App-Quantinova.ai

TPS8573 : SAKK 16/14: Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)A multicenter single-arm phase II trial.

Researchers

Presenter

  • Sacha Rothschild

Principal Investigators

  • Alfred Zippelius

  • Spasenija Savic

  • Michel Gonzalez

  • Walter Weder

  • Alexandros Xyrafas

  • Corinne Rusterholz

  • Miklos Pless

Medical Centers

  • University Hospital Basel, Basel, Switzerland

  • Institute for Pathology, University Hospital Basel, Basel, Switzerland

  • Department of Thoracic Surgery, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

  • Department of Thoracic Surgery, University Hospital, Zurich, Switzerland

  • SAKK - Swiss Group for Clinical Cancer Research, Coordinating Center, Bern, Switzerland

  • SAKK, Bern, Switzerland

  • Cantonal Hospital Winterthur, Winterthur, Switzerland

Locations

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • N/A

Drug/Treatment

  • Durvalumab

  • Docetaxel

  • Cisplatin

Outcome

  • N/A

Study Design

  • Single Arm

  • Multicenteric

Phase

  • II

Study Id's

  • NCTP000001480

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved